Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
复制标题
趋化因子 CCL27 是一种新型血浆生物标志物，用于识别 Epstein-Barr 病毒衣壳抗原特异性 IgA 血清阳性人群中的鼻咽癌患者。
DOI：
10.1186/s12885-017-3718-2
复制
发表时间：
2018-01-02
期刊：
影响因子：
3.8
通讯作者：
Liu WL
中科院分区：
文献类型：
--
作者：
Mao MJ;Xue N;Wang XP;Chi PD;Liu YJ;Huang Q;Dai SQ;Liu WL
目的探讨趋化因子CCL27对EB病毒衣壳抗原特异性IgA(VCA-IgA)阳性人群中早期鼻咽癌患者的预测价值。采用双抗体夹心法对104例鼻咽癌患者、112例VCA-IgA阳性健康献血员和140例VCA-IgA阴性正常人血浆中CCL27进行检测。应用免疫组织化学方法检测20例VCA-IgA阳性健康献血者和20例鼻咽癌患者鼻咽组织中CCL27的表达。VCA-IgA阳性健康献血员血浆CCL27水平(607.33±218.81)pg/ml显著高于鼻咽癌患者组(437.09±217.74，P=0.0001)和早期鼻咽癌患者组(463.85±226.17，P=0.0126)。VCAIgA阴性的正常人血浆CCL27水平(358.22±133.15)pg/ml显著低于VCAIgA阳性的健康献血员(P<0.0001)和鼻咽癌患者(P=0.0113)。在20例VCA-IgA阳性的健康献血者鼻咽组织标本中有16例(80%)检测到CCL27蛋白，在20例鼻咽癌患者的肿瘤组织标本中有3例(15%)表达CCL27蛋白。CCL27水平与VCA-IgA滴度及血浆EBV DNA含量无相关性。受试者工作特征(ROC)曲线显示，血浆CCL27水平鉴别鼻咽癌患者和VCAIgA阳性健康献血员的敏感性为67.00%，特异性为73.10%，ROC下面积为0.725(95%可信区间：0.657~0.793)。进一步分析发现，CCL27可区分早期鼻咽癌患者和VCAIgA阳性健康献血员，其ROC值为0.712(95%CI：0.560~0.865)，敏感性为59.80%，特异性为84.60%。趋化因子CCL27可成功识别VCA-IgA阳性人群中的鼻咽癌患者。
To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA). CCL27 in plasma samples from 104 NPC patients, 112 VCA-IgA–positive healthy donors, and 140 VCA-IgA–negative normal subjects was measured by ELISA. Expression of CCL27 in nasopharyngeal tissue from 20 VCA-IgA–positive healthy donors and 20 NPC patients was examined by immunohistochemical staining. Levels of CCL27 in the plasma of VCA-IgA–positive healthy donors (607.33 ± 218.81 pg/ml) were significantly higher than the levels in all NPC patients (437.09 ± 217.74, P = < 0.0001) and in the subset of patients with early stage NPC (463.85 ± 226.17, P = 0.0126). Plasma CCL27 levels were significantly lower in the VCA-IgA–negative normal subjects (358.22 ± 133.15 pg/ml) than in either the VCA-IgA–positive healthy donors (P < 0.0001) or the NPC patients (P = 0.0113). CCL27 protein was detected in 16 of 20 (80%) nasopharyngeal tissue samples from VCA-IgA–positive healthy donors and in 3 of 20 (15%) tumor tissue samples from NPC patients. There was no relationship between CCL27 levels and VCA-IgA titers or plasma EBV DNA content. Receiver operating characteristic (ROC) curves demonstrated that plasma CCL27 levels had a sensitivity of 67.00%, a specificity of 73.10%, and an area under the ROC of 0.725 (95% confidence interval [CI]: 0.657–0.793) for distinguishing between NPC patients and VCA-IgA–positive healthy donors. Further analysis showed that CCL27 levels could distinguish between early stage NPC patients and VCA-IgA–positive healthy donors with an area under the ROC of 0.712 (95% CI: 0.560–0.865), a sensitivity of 59.80%, and a specificity of 84.60%. Chemokine CCL27 could successfully identify NPC patients within a VCA-IgA–positive population.
登录
查看更多内容
影响因子：
6.2
作者：
Shao, JY;Li, YH;Zeng, YX
通讯作者：
Zeng, YX
影响因子：
5
作者：
LIN, TM;YANG, CS;HIRAYAMA, T
通讯作者：
HIRAYAMA, T
影响因子：
8.4
作者：
Simonetti, O;Goteri, G;Offidani, A
通讯作者：
Offidani, A
影响因子：
5
作者：
Liu, Zhiwei;Ji, Ming-Fang;Cao, Su-Mei
通讯作者：
Cao, Su-Mei
影响因子：
14.5
作者：
Zlotnik, A
通讯作者：
Zlotnik, A